By Jack Bradley, Staff Writer On February 14, Verax Biomedical Inc. filed an antitrust suit in federal court against the American Red Cross (“ARC”) alleging that it had used its position within the blood transfusion market to monopolize platelet treatment.[1] Verax also alleged that ARC published false statements about Verax’s […]
